2月13日，复星医药（600196/02196）发布公告，控股子公司吉斯美（武汉）制药有限公司就顺铂注射液的药品注册申请获国家药品监督管理局受理。
该药品为公司自主研发的化学药品，拟用于治疗转移性睾丸肿瘤、转移性卵巢肿瘤及晚期膀胱癌。截至2026年1月，公司针对该药品的累计研发投入约为469万元（未经审计）。根据IQVIACHPA最新数据，2024年顺铂注射液在中国境内（不包括港澳台地区）的销售额约为1.65亿元。
此次药品注册申请获受理预计不会对公司现阶段业绩产生重大影响，但药品上市后的销售情况仍存在较大不确定性，可能受到用药需求、市场竞争和销售渠道等多种因素的影响。
2025年前三季度，复星医药实现收入293.93亿元，归母净利润25.23亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.